Compounders Research Compare

Aclarion, Inc.(ACON)

Medical - Healthcare Information Services · Broomfield, CA

$2.29-0.05 (-2.14%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Aclarion, Inc.

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Broomfield, CA

11 employees

www.aclarion.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Brent Ness

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T20:25:19.052Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:25:19.052Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 6,600,630
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 16,285,462
TTM operating EBITDA · period ending 2026-06-30: -9,468,166

FMP input reference: 1aa4897ea94b4447735fa2b7e4a8bb5a18d1bcefabda34b81af7232f4abbcb6a

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACON EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ACON Competitors' EV/EBITDA Ratio

Aclarion, Inc.

Current

Market Cap

$6.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Ensysce Biosciences, Inc.

Market Cap

$6.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Enveric Biosciences, Inc.

Market Cap

$6.58M

EV/EBITDA Ratio

N/A

TTM Avg

34.26x

3Y Avg

34.26x

5Y Avg

668.76x

Bolt Biotherapeutics, Inc.

Market Cap

$6.74M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Biomerica, Inc.

Market Cap

$6.61M

EV/EBITDA Ratio

N/A

TTM Avg

96.60x

3Y Avg

88.71x

5Y Avg

504.98x

Exicure, Inc.

Market Cap

$6.88M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Femasys Inc.

Market Cap

$6.28M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA BIO, Inc.

Market Cap

$7.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curanex Pharmaceuticals Inc Common Stock

Market Cap

$7.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Scienture Holdings, Inc.

Market Cap

$6.11M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Aclarion, Inc. (ACON)	$6.60M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.60M	N/A	N/A	N/A	N/A
Enveric Biosciences, Inc. (ENVB)vs ›	$6.58M	N/A	34.26x	34.26x	668.76x
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.74M	N/A	N/A	N/A	N/A
Biomerica, Inc. (BMRA)vs ›	$6.61M	N/A	96.60x	88.71x	504.98x
Exicure, Inc. (XCUR)vs ›	$6.88M	N/A	N/A	N/A	N/A
Femasys Inc. (FEMY)vs ›	$6.28M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.04M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.07M	N/A	N/A	N/A	N/A
Scienture Holdings, Inc. (SCNX)vs ›	$6.11M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics